Diabetes Drug Cuts Vision Loss Risk by 37% in Study

Millions of people already take metformin for diabetes, and new research suggests it might be protecting their vision at the same time.

Scientists at the University of Liverpool discovered that people over 55 with diabetes who took metformin were 37% less likely to develop intermediate age-related macular degeneration compared to those not taking the drug. They tracked 2,000 patients over five years using routine eye screening photos.

Age-related macular degeneration, or AMD, is one of the leading causes of permanent blindness in older adults. Right now, most people with AMD have no treatment options available.

The researchers carefully accounted for factors like age, sex, and how long patients had diabetes to make sure these weren't skewing the results. The connection between metformin and better eye health held strong even after these adjustments.

"Most people who suffer from AMD have no treatment, so this is a great breakthrough in our search for new treatments," said Nick Bear, the ophthalmologist who led the research. The next step is testing metformin specifically as an AMD treatment in clinical trials.

Why This Inspires

What makes this discovery particularly exciting is that metformin is already widely available and affordable. The drug went off-patent years ago, making it one of the most accessible medications for managing blood sugar.

Scientists believe metformin's anti-inflammatory and anti-aging properties may be protecting the retina from damage. These same qualities have made researchers curious about the drug's potential benefits beyond diabetes for years.

The medication is generally safe, though some people experience digestive side effects or vitamin B12 deficiency. Doctors already know how to monitor for these issues in diabetes patients.

The study was observational, meaning it shows a link but doesn't prove metformin directly caused the improvement. It also only looked at people with diabetes, so researchers don't yet know if it would help protect vision in people without the condition.

Still, the findings open an exciting door for the millions of older adults facing vision loss with few options available to them.